ZVRA Receives Proxy Advisory Firms' Recommendations for Annual Meeting | ZVRA Stock News - GuruFocus
21 hours ago • Google News
Zevra Therapeutics Inc. (ZVRA)
US$ 7.2-0.55%
Price Chart
Key Statistics
Market Cap
$ 473.53M
P/E Ratio
0.00
Revenue (TTM)
$ 40.59M
Volume
370.92K
52W High
$ 9.76
52W Low
$ 4.20
Dividend Yield
0.00%
Beta
1.87
Technicals
50-Day MA
7.6476
200-Day MA
7.9446
52 Week High
9.76
52 Week Low
4.2
About ZVRA
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
Employees
59
Headquarters
Celebration, FL
CEO
Mr. Neil F. McFarlane
Latest News
Rare Disease Leader Zevra Therapeutics Reveals Growth Strategy at Citizens Conference - Stock Titan
3 weeks ago • Google News
ZEVRA THERAPEUTICS Earnings Results: $ZVRA Reports Quarterly Earnings - Nasdaq
2 weeks ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg